化工涨的比创新药还多？

Core Insights - The chemical sector has outperformed the innovative pharmaceutical sector recently, with a notable increase of 3.7% in chemical stocks, leading to a total profit of over 20% from a rotation strategy between chemicals and green energy [3][20]. - The innovative pharmaceutical sector has also seen significant gains, with a current increase of 4.76% and a price-to-earnings (P/E) ratio of 31.83, which is relatively low compared to its historical average [5][6]. - The innovative pharmaceutical sector's growth this year has been driven by earnings rather than mere price increases, indicating a strong underlying performance [8]. Chemical Sector - The chemical sector has shown a profit of 15% after a recent bottom-fishing strategy, with the price now exceeding the previous selling price by 7% [2][3]. - The rotation strategy between chemicals and green energy has yielded a combined profit of over 20% [3][20]. Innovative Pharmaceutical Sector - The innovative pharmaceutical sector has experienced a significant rise, with a reported profit of 93.73% on a specific ETF holding, which is expected to exceed 100% with recent gains included [9]. - Despite the substantial price increase this year, the P/E ratio remains at a reasonable level, suggesting potential for further growth [6][8]. Market Trends - The market is witnessing a shift towards more stable investments, with investors inquiring about the potential for further investments in dividend and fixed-income funds [16][19]. - The overall sentiment indicates that while the market has recovered significantly, future profits will increasingly depend on identifying sectors with potential for substantial earnings growth [18].